Reach

Throughout our 150-year history, we have worked to address some of the world's most pressing health challenges, including infections, diabetes, depression, cancer and obesity. The medicines we discover, develop and manufacture support millions of people globally, and we continue to expand our efforts to improve access and affordability across the world.

Our global health efforts focus on NCDs and on people living in resource-limited communities in the U.S. and LMICs.

The human toll of NCDs is growing. According to the World Health Organization, NCDs are the leading cause of death worldwide, particularly in LMICs, where infrastructure and resources can be limited. Lilly’s current portfolio of medicines and pipeline are focused on NCDs. Beyond our scientific innovations, we leverage our deep expertise to help close healthcare gaps and reduce the growing burden of NCDs for people living in these settings.

Pricing and Affordability Around the World

Our products are sold in approximately 90 countries. Each country values medications and innovation differently and must balance competing demands for finite resources. Pricing medicines to achieve the optimal balance between affordable patient access and sustained investment in innovative treatments is complex. We evaluate country-specific conditions when pricing medicines on a market-by-market basis.

Patients in resource-limited settings in LMICs face economic circumstances that may limit their access to medicines and health services. We deploy dedicated efforts to help provide access to high-quality, affordable medicines and strengthen healthcare systems in these markets. We also support efforts to decrease the final price of medicines to patients in these countries, such as minimizing out-of-pocket costs and limiting markups across the supply chain.

Lilly Support of Universal Health Coverage

The global call for Universal Health Coverage (UHC) as part of the United Nations Sustainable Development Goals (UN SDGs) aims to ensure everyone has access to quality health services and medicines without financial hardship. Achieving this requires collaboration across multiple sectors, including the private sector, to address UHC financing and implementation gaps. Through our alignment to the UN SDGs, we play a role by developing new medicines, extending the reach of our existing medicines, and supporting healthcare system improvements.

Lilly 30x30

In 2016, we launched Lilly 30x30, a company-wide initiative to expand access to quality healthcare for 30 million people living in resource-limited settings, annually by 2030. Lilly 30x30 includes strategic collaborations with external organizations and support for nonprofit organizations. By reaching across industry boundaries and working with leading healthcare organizations, providers, regulators, and governments, we deliver innovative solutions to help address access challenges and strengthen healthcare systems.

Our approach employs a mix of pipeline development, access programs, and philanthropic initiatives. Our efforts focus on therapeutic areas where we have deep technical expertise, including diabetes, obesity, and oncology. In each of these areas, we prioritize high-impact, scalable and sustainable solutions for people living in resource-limited communities, by supporting and leveraging local and regional capabilities.

A senior executive steering committee, reporting to the CEO, oversees Lilly 30x30, ensuring priorities and progress milestones align with and enhance our business strategy and mission.

Our 30x30 efforts are organized around three pillars:

Pipeline

Through our pipeline pillar, we focus on discovering new medicines, repurposing internal assets, and collaborating externally to address diseases that disproportionately affect people in resource-limited settings. Our efforts include targeted development of assets for LMICs and venture capital investments focused on near- and long-term healthcare solutions in these markets. Beginning in 2023, we launched a process to systematically evaluate internal assets to identify product development and access planning strategies for LMICs with the goal of accelerating our reach and scale. We are also a top-tier investor in the Antimicrobial Resistance (AMR) Action Fund.

Programs

Through our programs pillar, we work to strengthen existing efforts and develop new approaches to accelerate access to our medicines and improve healthcare for people living in resource-limited settings. This includes commercial product distribution in LMICs and U.S. resource-limited communities, patient support programs, and manufacturing and public-private partnerships.

We offer a range of affordability solutions through global patient support and copay assistance programs across key therapeutic areas. These programs help patients navigate access and reimbursement challenges, offer disease and health management support, and provide information on Lilly medicines and device training.

On the manufacturing side, we are building public-private partnership-based solutions to expand access to our products in countries where we currently have no or limited presence. These collaborations enable regional manufacturers to produce and supply high quality, affordable medicines, extending our reach without requiring direct commercial infrastructure in every market. Our collaboration with EVA Pharma, launched in 2022, is an example of this model. The collaboration aims for EVA Pharma to deliver a sustainable supply of affordable human and analog insulin to people living with type 1 and type 2 diabetes in LMICs in Africa and beyond. In 2024, the collaboration reached two milestones: the registration and release of the first locally manufactured insulin glargine injection in Egypt, and an agreement to license certain baricitinib manufacturing know-how to enable EVA Pharma to manufacture and supply the product across LMICs in Africa. Discovered by Incyte and licensed to Lilly, baricitinib is for the treatment of rheumatoid arthritis, alopecia areata, atopic dermatitis, and COVID-19.

Philanthropy and Other Initiatives

Through our pillar related to philanthropy and other initiatives, we support collaborations and engagements that strengthen health systems, expand access to quality healthcare, and improve health outcomes. Our efforts align with the World Health Organization’s health system strengthening priorities by building healthcare workforce capacity, improving service delivery and digital systems, and enabling community-led primary healthcare closer to patients. We also generate insights that inform policy and support the scale-up of proven, cost-effective healthcare access solutions.

Lilly 30x30 Global Health Highlights

We are active in 38 engagements globally, with a focus on LMICs in South and Southeast Asia, Sub-Saharan Africa, as well as Mexico and resource-limited populations in the United States. These efforts span our key focus areas, including diabetes, obesity, cancer, and health systems strengthening. We collaborate with organizations working at global, regional, national and local levels, including the following:

UNICEF: We support UNICEF USA through multi-year initiatives extending through 2032, designed to strengthen primary healthcare systems and improve prevention, diagnosis, and long-term management of childhood and adolescent NCDs—including type 1 diabetes, congenital and rheumatic heart disease, sickle cell disease, and chronic respiratory conditions. These efforts focus on training frontline healthcare workers, integrating NCD care into national systems starting at the community level, and supporting caregivers and communities. Note: UNICEF does not endorse any company, brand, product, or service.

Life for a Child: We have provided longstanding support related to the Life for a Child program, which supports diabetes centers caring for children and youth living with diabetes in resource-limited settings. The program provides insulin, delivery devices and monitoring supplies, and supports medical care, diabetes education, complications screening and management, and advocacy. In 2021, we expanded our support of Direct Relief, including increased contributions of mealtime and basal insulins, reusable pens, and financial support for storage, packing, and shipping costs related to their support of the Life for a Child program.

United States-Mexico Foundation for Science (FUMEC): We support efforts of the United States-Mexico Foundation for Science to advance the prevention and long-term management of obesity, diabetes, and hypertension in resource-limited areas of Mexico by embedding a Personalized Public Health Model into primary healthcare. The initiative leverages a digital health ecosystem to strengthen early detection, continuity of care, and systems-level decision making for NCDs.

CEO Roundtable (CEORT) In-Country Patient Access (ICPA) Programs: Alongside separate support provided by the Gates Foundation and industry peers, through CEORT programs, we support U.S. charitable organizations advancing implementation of NCD programs in Sub-Saharan Africa. Active initiatives in Ghana, Kenya, and Tanzania focus on building community health worker capacity, deploying point-of-care diagnostics, integrating AI-enabled training for frontline health workers, and strengthening NCD care delivery at the community level.

AMPATH (Academic Model Providing Access to Healthcare): Through product contributions to the Catholic Medical Mission Board, we support the AMPATH Kenya initiative, helping people living with cancer, diabetes, and mental health disorders. We also support the Indiana University Foundation in their efforts related to the AMPATH Mexico initiative, a charitable effort to transform primary healthcare for NCDs by training and deploying community health workers and early-career healthcare providers.

Diabetes Impact Project: Indianapolis Neighborhoods (DIP-IN): Launched in 2018, DIP-IN focuses on three Indianapolis communities with high diabetes prevalence. The project leverages resident steering committees to lead neighborhood-based health promotion initiatives, expanding access to health-supporting resources and improving overall health. It includes neighborhood- and clinic-based community health workers to identify people living with or at risk of developing diabetes and connect them to quality care. Led by Indiana University Richard M. Fairbanks School of Public Health and other organizations, the project has demonstrated significant reduction in HbA1c levels among participants working with clinic-based community health workers.

Product Contributions: Lilly and its affiliates provide our medicines to charitable organizations that offer free products to qualifying patients around the world, including product contributions used by third parties for patient assistance programs and humanitarian efforts. Eligibility is determined by each tax-exempt organization.

As part of these efforts, we donate medications to the Lilly Cares Foundation (Lilly Cares), a separate U.S. nonprofit organization. Through the Lilly Cares Patient Assistance Program, qualifying patients in the U.S. with financial need can receive prescribed Lilly medications at no cost.

Multi-Stakeholder Collaborations to Advance the Sustainable Development Goals

We are members of several multi-stakeholder collaborations focused on tackling global health challenges, including the Access to Oncology Medicines Coalition (ATOM), the Coalition for Access to NCD Medicines and Products, the NCD Alliance, the Partnership for Quality Medical Donations (PQMD), and Access Accelerated.

WHO Foundation

In late 2025, we entered into a collaboration with the WHO Foundation to strengthen health systems for obesity care. Through this collaboration, the WHO Foundation will support efforts to elevate obesity as a public health priority and strengthen the systems needed to respond equitably and sustainably in resource-limited settings. The collaboration focuses on strengthening primary healthcare system readiness—including workforce training, stigma-free care, and foundational capacities such as screening, diagnosis, and long-term care.

AMR and AI

In support of our investment in the Antimicrobial Resistance (AMR) Action Fund, we invested in a partnership with OpenAI in 2024 to assess generative AI and large language model capabilities for accelerating early-stage molecule discovery. Key outcomes included enabling rapid evaluation of frontier AI models for drug discovery workflows, informing the development of our internal AI platform for hosting and scaling models on proprietary research data, and initiating subsequent research collaborations with additional partners for wet lab chemistry and biology applications.

Product Contributions

In 2025, Lilly and its affiliates provided more than $3.2 billion in medicines to charitable organizations, including national relief organizations and the Lilly Cares Foundation (a separate U.S. nonprofit organization), which provide Lilly medications for free to qualifying patients. Products are valued at wholesale acquisition cost, and eligibility is determined by each tax-exempt organization.

Our support related to the Life for a Child program enabled more than 65,000 children and youth with diabetes in resource-limited settings to access Lilly insulin in 2025, up from 53,000 in 2024. This expansion was supported by the addition of Humalog cartridges provided by Lilly to Direct Relief.

Achieving our 30x30 goal five years ahead of schedule marked an important milestone in Lilly's global health journey and underscored the scale of opportunity still ahead. More than a billion people living with diabetes and obesity still face barriers in accessing the medicines they need. Building on the strong foundation established through 30x30, Lilly is developing a new commitment to expand its efforts to address the growing burden of diabetes and obesity in resource-limited settings worldwide. This next chapter will reflect Lilly's continued ambition to close the gap in access to cardiometabolic health medicines between higher-income and resource-limited settings.

Additionally, in May 2026, we announced a six-year collaboration with UNICEF USA aiming to improve non-communicable disease (NCD) prevention and care for children, reaching over 30 million young people and caregivers across 21 LMICs. We committed $50 million to UNICEF USA, supporting UNICEF's efforts to strengthen primary healthcare systems to better prevent, detect and manage NCDs such as diabetes, congenital heart disease, sickle cell disease and respiratory illness in children and adolescents. It will also strengthen prevention, care and support for children living with overweight and obesity, helping reduce long-term health risks for children, their families and communities. This builds on the $21 million previously committed to UNICEF USA for the work UNICEF is supporting in resource-limited settings.

We plan to continue evolving our approach to pipeline development for LMICs, exploring new formulations, combinations, and delivery mechanisms designed to simplify therapy and reduce costs for resource-limited settings.

By advancing innovation, improving access, and supporting stronger health systems, we aim to help more people access life-changing medicines and live healthier lives. This next chapter reflects our belief that scientific breakthroughs achieve their greatest impact when they reach the people who need them most.

Resources

• Lilly Foundation

• Public Policy

Related Topics

• Innovate

• Approve

• Enable

• Supply